Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet-Reference-Cited by-同舟云学术

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Published:2010-01-21 Issue:3 Volume:115 Page:453-474
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Döhner Hartmut¹,Estey Elihu H.²,Amadori Sergio³,Appelbaum Frederick R.⁴,Büchner Thomas⁵,Burnett Alan K.⁶,Dombret Hervé⁷,Fenaux Pierre⁸,Grimwade David⁹,Larson Richard A.¹⁰,Lo-Coco Francesco¹¹,Naoe Tomoki¹²,Niederwieser Dietger¹³,Ossenkoppele Gert J.¹⁴,Sanz Miguel A.¹⁵,Sierra Jorge¹⁶,Tallman Martin S.¹⁷,Löwenberg Bob¹⁸,Bloomfield Clara D.¹⁹

Affiliation:

1. Department of Internal Medicine III, University of Ulm, Ulm, Germany;

2. Seattle Cancer Center Alliance, WA;

3. Department of Hematology, Tor Vergata University Hospital, Rome, Italy;

4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

5. Department of Hematology/Oncology, University of Münster, Münster, Germany;

6. Department of Haematology, University of Wales College of Medicine, Cardiff, United Kingdom;

7. Institut Universitaire d‘Hématologie Hôpital St. Louis, Assistance Publique-Hôpitaux de Paris, Paris, France;

8. Service d'Hématologie Clinique, Hôpital Avicenne, Bobigny, France;

9. Department of Medical and Molecular Genetics, Guy's King's and St. Thomas' School of Medicine, London, United Kingdom;

10. Department of Medicine and Cancer Research Center, University of Chicago, IL;

11. Department of Biopathology, University Tor Vergata and Santa Lucia Foundation at Centro Europeo per la Ricerca sul Cervello, Rome, Italy;

12. Department of Hematology, Nagoya University Hospital, Showa-ku, Japan;

13. Department of Hematology, Oncology and Hemostasis, University of Leipzig, Leipzig, Germany;

14. Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands;

15. Hematology and Bone Marrow Transplant Unit, University Hospital La Fe, Valencia, Spain;

16. Clinical Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;

17. Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL;

18. Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; and

19. The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus

Abstract

AbstractIn 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion–based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/115/3/453/1458437/zh800310000453.pdf

Reference314 articles.

1. Report of the National Cancer Institute-sponsored Workshop on Definitions of Diagnosis and Response in Acute Myeloid Leukemia.;Cheson;J Clin Oncol,1990

2. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia.;Cheson;J Clin Oncol,2003

3. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.;Swerdlow,2008

4. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.;Sanz;Blood,2009

5. The 2008 revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia: rationale and important changes.;Vardiman;Blood,2009

Cited by 2847 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chidamide induces cell cycle arrest via NR4A3/P21 axis upregulation to suppress relapsed and refractory acute myeloid leukemia;Biochemical and Biophysical Research Communications;2024-12

2. FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives;European Journal of Medicinal Chemistry;2024-11

3. Potential Correlation between Gene Mutations and Metabolic Changes in Acute Myeloid Leukemia;The Natural Products Journal;2024-10

4. Certainty in uncertainty: Determining the rate and reasons for reclassification of variants of uncertain significance in haematological malignancies;eJHaem;2024-09-12

5. Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia;European Journal of Haematology;2024-09-09